Expression of chondroitin sulfate proteoglycan 4 (CSPG4) in melanoma cells is downregulated upon inhibition of BRAF
Anti-chondroitin sulfate proteoglycan 4-specific antibodies modify the effects of vemurafenib on melanoma cells differentially in normoxia and hypoxia
Chondroitin sulfate proteoglycan protein is stimulated by interleukin 11 and promotes endometrial epithelial cancer cell proliferation and migration
Icariside II overcomes BRAF inhibitor resistance in melanoma by inducing ROS production and inhibiting MITF
Rapid and specific targeting of monoclonal antibody A33 to a colon cancer xenograft in nude mice.